WO2005016372A1 - Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals - Google Patents
Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals Download PDFInfo
- Publication number
- WO2005016372A1 WO2005016372A1 PCT/CA2004/000445 CA2004000445W WO2005016372A1 WO 2005016372 A1 WO2005016372 A1 WO 2005016372A1 CA 2004000445 W CA2004000445 W CA 2004000445W WO 2005016372 A1 WO2005016372 A1 WO 2005016372A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- plant
- free radicals
- protein
- lactoferrin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 42
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 42
- 239000000419 plant extract Substances 0.000 title description 14
- 239000000284 extract Substances 0.000 claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 12
- 241000192700 Cyanobacteria Species 0.000 claims abstract description 9
- 108010063045 Lactoferrin Proteins 0.000 claims description 62
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 62
- 229940078795 lactoferrin Drugs 0.000 claims description 62
- 235000021242 lactoferrin Nutrition 0.000 claims description 62
- 150000003254 radicals Chemical class 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 26
- 239000002184 metal Substances 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 238000006241 metabolic reaction Methods 0.000 claims description 8
- 239000002417 nutraceutical Substances 0.000 claims description 8
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 102000010445 Lactoferrin Human genes 0.000 description 61
- 230000000694 effects Effects 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 18
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 17
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 10
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- -1 free radical compounds Chemical class 0.000 description 5
- 229940094952 green tea extract Drugs 0.000 description 5
- 235000020688 green tea extract Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000004584 polyacrylic acid Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000003869 genetically modified organism Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010026206 Conalbumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101800004361 Lactoferricin-B Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to utraceutical products, with beneficial effect on health or prevention of physiological diseases.
- the invention relates to a composition based on poly-metal binding proteins and added products obtained from plant sources having desired biological and biochemical properties.
- Lactoferrin is a protein of 77 Da found in milk and in other malian secretion. ' This protein is an iron-binding protein, and many bioactivities were demonstrated in-vitro or in-vivo. This protein was related to a structural group of iron-binding protein containing transferrin and ovotransferrin, known for their biological activities. In its structure, a basic N-terminal motif is rich in tryptophane and arginine which make it possible to be responsible for some of the effects of the protein. Through pepsin hydrolysis, this protein release a peptide named lactoferricin which also have bioactivities.
- lactoferrin can be carried out by affinity chromatography, chromatography with a silica-type support, or by some types of ion-exchange chromatography * . ' All these techniques allow the production of lactoferrin with a purity of between 70 to 95%, and some commercially available lactoferrin are already on the market. Because of the interest of human lactoferrin as a compound in infant formula, some methods exist to produce this human protein in different genetically engineered species. The antibacterial activity of lactoferrin is the most documented feature. This comes directly from antibacterial activity or can be a result, of iron depletion by said lactoferrin in the environment of the bacteria.
- US Patent 6,172,040 proposes the use of lactoferrin immobilized in a . matrix substance for use as antimicrobial agent in food.
- lactoferrin iron, copper, zinc or manganese
- US Patent 5,296,464 for their different antibacterial activities. It is proposed that lactoferrin preparations be used in foods, on surfaces, or for topics applications. The use of lactoferrin is also proposed for therapy against acute or
- lactoferrin can be used in combination with other antimicrobial agents, respectively lactoperoxidase and beta- lactams, as oral therapeutic agents.
- lactoferrin can be used in combination with other antimicrobial agents, respectively lactoperoxidase and beta- lactams, as oral therapeutic agents.
- lactoferrin many other bio-activities of lactoferrin are known, . and some of them have been patented. Examples include the anti-heparinic effect, the anti-toxin effect against endotoxins, the wound-healing effects in ophthalmic preparation, the prebiotic effect on bifidobacteria, the growth factor effect for use in infant formula, its activities in iron transport, antioxidant activities or use as metal chelator.
- lactoferrin peptides can have some bioactivities, there are several possible applications of lactoferrin hydrolysates or lactoferrin peptides on different health targets.
- ROS reactive oxygen species
- enzymes such as superoxide dismutase, catalase, glutathione transferase, glutathione peroxidase and glutathione reductase
- antioxidants such as tocopherols, ubiquinone, ubiquinol, ascorbic acid and dehydroascorbic acid.
- One aim of the present invention is ' to provide a biocompatible composition for modulating physiological mechanisms in a human or an animal comprising ' a polymetal-binding protein and a plant or cyanobacterial extract having antioxidant activity.
- the desired modulation may be increasing or reducing a metabolic or physiologic reaction.
- the biocompatible composition of the present invention can be used as a . nutraceutical, a therapeutical or a cosmeceutical composition.
- the polymetal-binding protein may be, but is not limited to, lactoferrin, or related proteins or derivatives or fragments thereof. Again, it will be recognized by someone skilled in the art that the polymetal-binding protein can be capable of modulating a metabolic or physiological reaction by binding at least one metal ion selected from the group consisting of iron, magnesium, copper, zinc, and manganese.
- polymetal-binding protein is preferably at a concentration between 50 to 1500 mg per dose or in concentration allowing the composition to act on the targeted metabolic or physiologic reaction.
- Another object of the present invention is to provide a nutraceutical or cosmeceutical composition for modulating or activating a metabolic body reaction in a human- or an animal.
- This composition may comprise between about 50 and 1500 mg of lactoferrin or related iron binding proteins or their peptides per portion, and at least one plant extract with antioxidant properties which improve the action of lactoferrin or related iron binding proteins or their peptides on a metabolic reaction
- Another object of the present invention is to provide a therapeutical composition for modulating a metabolic body reaction in a human or an animal.
- This composition comprises: a) between 50 and 1500 mg of lactoferrin or related iron binding proteins or their peptides per day; and b) a plant extract with antioxidant properties which improve the action of lactoferrin or related iron binding proteins or their peptides on a metabolic reaction.
- a further object of the present invention is to provide a topical composition for modulating a metabolic body reaction in a human or an animal.
- This composition comprises: a) between 50 and 1500 mg of lactoferrin or related iron binding proteins or their peptides per portion; and b) a plant extract with antioxidant properties which improves the action of lactoferrin or related iron binding proteins or their peptides on a metabolic reaction
- the modulation of .a metabolic reaction includes maintaining, restoring, reducing or increasing the rate of the metabolic reaction, the latter being an intestinal, an immune, an inflammatory, a skin, a neurological, a blood, a neuronal, a muscular, a hepatic, a cardiovascular, a renal, a gastric, a digestive, a pancreatic, an endocrine, a bone, a joint, or a respiratory reaction.
- the composition of the present invention can be, for example but is not limited to, a food composition or a cosmeceutical composition.
- a biocompatible composition for modulating free radicals quantity or related damages in a human or an animal cell, tissue, or biological fluid comprising a polymetal-binding protein and plant or cyanobacterial extract having antioxidant activity.
- the polymetal-binding protein is preferably lactoferrin, or a related protein, or derivatives or fragments thereof.
- the biocompatible composition of the present invention is characterized by, depending on needs, being capable to increase or reduce the quantity of free radicals and related damages into cells, tissues or body fluids in humans or animals.
- the polymetal-binding protein is capable of modulating free radical quantity by binding at least one metal ion selected from the group consisting of iron, magnesium, copper, zinc, and manganese. Also, the polymetal-binding protein is preferably at a concentration between 50 to 1500 mg/dose or in concentration allowing the composition to act on the targeted metabolic or physiologic reaction..
- the plant or cyanobacterial extract used in producing the composition of the present invention can be raw or refined, and can contain chromophores.
- the biocompatible composition of the present invention can be used as a nutraceutical, a therapeutical, or a cosmeceutical composition.
- Another aim of the present invention is to provide a method of alleviating or preventing inflammation in a human or animal comprising administering to said human or animal a combination of poly-metal binding protein and plant or cyanobacterial extract.
- the combination that cause the reduction of free radicals quantity into a human or ⁇ animal body is completed by administering simultaneously or separately the poly-metal binding protein and the plant or cyanobacterial extract.
- the inflammation can be partly or totally due to free radicals.
- Another aim of the present invention is to provide the use of poly-metal protein combined with at least one of plant o cyanobacteria extract in the preparation of a composition for modulating free radical quantity or free radical related damages in body cells, tissues, or fluids. This use can be carried out for reducing the quantity of free radicals in or the damages induced by the free radicals in body cells, tissues, or fluids.
- poly-metal protein combined with at least one of plant or cyanobacteria extract in the preparation of a composition for alleviating or treating inflammation in a human or an animal.
- the lactoferrin is obtained from milk, whey or genetically modified organisms.
- Lactoferrin peptide are obtained by hydrolysis of this protein with enzyme obtained ' from natural sources that include digestive, microbial, animal or plant source, or with genetically or chemically engineered enzymes.
- Related iron-binding protein are obtained from eggs, blood, serum, plasma or tissues of vertebrates, or genetically modified organisms, peptides from iron-binding proteins are produced by the hydrolysis of these proteins with enzyme obtained from natural source that include digestive, microbial, animal or plant sources or with genetically or chemically engineered enzymes.
- polymetal binding protein as used herein is intended to mean, for example, proteins which can bind metals, such as iron, zinc, copper or other metals, for example lactoferrin or related proteins.
- related proteins as used herein is intended to mean, for example metal-binding proteins than lactoferrin such as transferrin obtained from blood or vertebrate tissues, or ovotransferrin obtained from eggs. Geneticaly engineered proteins using genes or genes fragments of these proteins are also included on the definition of this term.
- peptides as used herein means fragments of these proteins obtained by hydrolysis of these proteins by enzymes obtained from natural sources that include digestive, microbial, animal, or plant sources, or with genetically engineered enzymes.
- plant extracts as used herein is intended to mean plant extracts obtained from cells, leaves, stems or stalks of plants, algae, or cyanobacteria.
- the plant extracts have antioxidant properties.
- dose is intended to mean a sufficient amount of protein which must be used by human or animal each day to give the desired effect on the modulation of the metabolic reaction which is targeted.
- an effective concentration of a free radical inhibitor or “concentration which is effective to inhibit free radical degradation” as used herein means a concentration of a free radical inhibitor compound that is capable of reducing the amount of free radical compounds as compared to the amount of free radical compounds obtained in the absence of the free radical inhibitor compound.
- Methods of determining the ability of a compound to inhibit free radical formation or free radical-induced degradation are well known in the art. For example, a method for determining the free radical inhibitory capacity of a compound is based on the ability of such a compound to inhibit free radical polymerization of acrylic acid to polyacrylic acid.
- a suitable assay for demonstrating an effective concentration of a selected free radical inhibitor compound is an assay which determines the ability of such a compound to inhibit the polymerization of a 30% aqueous solution of acrylic acid at 85°C. after initiation with 0.1% azobisisobutyronitrile.
- the inhibitory capacity of such a. compound is determined by comparing the percentage of polyacrylic acid formed in the presence and absence of a predetermined concentration of the selected free radical inhibitor compound, with inhibition being demonstrated by a detectable decrease in the amount of polyacrylic acid formed in the reaction mixture containing the inhibitor as compared to the amount of polyacrylic acid formed in the reaction mixture to which an inhibitor was not added.
- the amount of polyacrylic acid formed is inversely related to the amount of acrylic acid (i.e., monomer) remaining in the reaction mixture at the end of the assay.
- the amount of acrylic acid may be routinely determined by measuring the iodine value of the reaction mixture or by other methods known in the art for determinating unsaturation.
- a well-known free radical inhibitor compound such as hydroquinone mono methyl ether (HQMME) may be used as a standard inhibitor compound in the assay.
- Other methods commonly used are the TBARS (ThioBarbituric Acid Reactive Substance) determination, which is the determination of Malondialdehyde (MDA) created when lipids are submitted to peroxidation by free radicals.
- MDA Malondialdehyde
- Inhibition of MDA formation when Fe3+ and ascorbic acids (which are able to generate free radical formation) are mixed with phosphatidyl choline (a lipid) is a good marker for free radical inhibition.
- Another available method is the ability to neutralize the DPPH (2,2-Diphenyl-l-picrylhydrazyl), which is a stable free radical in solution.
- a simple spectrometric test allows the determination of DPPH which is neutralized by a free radical inhibitor compound.
- Cell culture tests are also available, which are related ' to the characterization of oxidative stress markers (Nitric Oxide (NO) or iNOS (inducible Nitric Oxide Synthase) for example) induced by pro-oxidative compounds added the cell culture media. Inhibition of the oxidative stress markers by a free radical inhibitor compound are commonly used to determine inhibition of the free radical degradation on cellular models.
- Fig. 1 illustrates the effect of proinflammatory compounds on iNOS expression in Caco-2 cells
- Fig. 2 illustrates the effect of. different concentrations .of lactoferrin on iNOS expression by Caco-2 cells inflamed with CM1;
- . . Fig. 3. illustrates the effect of the algae extract and lactoferrin on iNOS expression by Caco-2 cells inflamed with CM1 ;
- Fig. 4 illustrates the effect of green tea extract and lactoferrin on iNOS expression by Caco-2 cells inflamed with CM1.
- composition of the invention comprises botanical extracts having antioxidant properties, combined VvTTH a polymetal-binding protein, such as,* but not limited to, lactoferrin related binding proteins or derivatives or fragments thereof. It has been surprisingly observed that the plant extracts have a . significant synergetic effect which enhances or completes the effect of a polymetal- binding protein or their derivatives or fragments thereof.
- a new nutraceutical or cosmeceutical composition allowing the prevention, treatment or restoration of physiological functions in an human or an. animal, through . oral administration or topical application.
- the composition is principally composed of two fractions, one being a polymetal-binding protein, such as lactoferrin or related binding proteins or peptides from lactoferrin or related binding proteins and another being a botanical or cyanobacterial extract with antioxidant properties.
- lactoferrin is used in combination- with other agents, to completing its activities. It is the case of its i munostimulatory effect, which is completed, for example but not limited to, by the use of colostrum in the finished product.
- plant extracts are synergistically used for health, or prevention or treatment of diseases.
- some compounds may be used for examples for treatment of cancer, neurological diseases, immune problems, prostate diseases, hepatic disorder, or for their antiviral or antifungal activities.
- plant extracts, raw or refined have antioxidant activities, and this characteristic has been exploited since a . long time for its positive effects on health. ' It is the case for quercetin and rutin, carotenoids, cysteine derivatives or polyphenols or procyanidins.
- complex extracts of botanical sources have an antioxidant effect and can be used for their antioxidant properties in food, cosmetics, or neutraceutical formulations. These extracts can be used for examples as food preservation, for skin protection, or for use in food or nutraceutical compositions for example.
- the combination of these two fractions, lactoferrin. and plant extract synergistically improves the activity of the polymetal-binding protein or their peptides, to modulate a body metabolism involved in a physiological reaction.
- the physiological reaction can be a processing reaction in normal conditions, or a reaction following or being part of a disease or a disorder.
- the disease or disorder can be acquired, such as for example but not . limited to, following an accident or intoxication, or naturally occurring as it is the case for genetically transmitted metabolic disorders.
- Lactoferrin or its derivatives allow the binding or different metal ions, such as, but not limited to, iron, copper, zinc or manganese, which are ions involved in a high variety of physiological reactions. It is recognized for its antibacterial, antiviral and antifungal activities, as well ' as for . its immunomodulatory, anti-tumor or anti-inflammatory effects.
- the combination of this polymetal-binding protein with a plant extract has proven to give body effects that were not believed possible to suspect before.
- the plant or cyanobacterial extracts have antioxidant properties, and more preferably contains chromophores.
- the extracts can be in form of flakes, or can be raw, crude, or refined at different levels into powder, for example.
- the extract can be separated from impurities or other extraneous substances before being mixed with the poly-metal binding proteins.
- the plant or cyanobacterial extract can be processed before being mixed with the poly-metal binding protein.
- the extract portion of the composition of the invention can be administered at the same time of shortly before or after administration of the poly-metal binding proteins.
- the combination plant or cyanobacterial extract and poly-metal binding protein is preferably orally administered, but can also be topically applied onto the human or animal body.
- the present invention entails a body cells or tissues treatment composition or capable of inhibiting, removing or neutralizing free radical degradation of the body cells or tissues, which may comprises a nutraceutical base composition or a topical cosmetic base composition, which contains a concentration of a plant or cyanobacterial extract combined with a poly- metal binding protein.
- the invention also relates to the use of lactoferrin or related metal- binding proteins or fragments thereof.
- These polymetal-binding proteins can be produced from different sources, preferably from milk, whey, egg, serum, plasma or blood, but can also be originated from genetically modified organisms.
- the protein itself can be of hen, bovine, human, porcine, ovine, caprine, or other vertebrate origin, preferably hen, bovine or human, or can be a chimeric protein obtained by molecular biology.
- the peptides can be produced by chemical or enzymatic hydrolysis of lactoferrin or related metal-binding proteins, preferably by enzymatic hydrolysis, preferably with digestive enzyme.
- the peptides can be genetically engineered organisms by using lactoferrin or related metal-binding proteins, or gene fragments and expression of these fragments in an appropriate organism, followed by purification of the peptides.
- the composition comprising poly-metal binding protein mixed with plant extract is . used to neutralise the effect of free radicals into the body of a human or an animal.
- the composition is useful in reducing the flow or circulation of free radicals involved, directly or indirectly, into a metabolic reaction , such as in body inflammation processes.
- Inflammation which can be induced by several factors like for examples chemical compounds, physical agents (like UN), infections or a ⁇ toimmune disorders, and which is part of many diseases, like atherosclerosis, rheumatic disease, arthritis, intestinal bowel disease, or skin disorder, induce the activation of several oxidant-generating enzymes such as ⁇ ADPH (reduced, form of nicotinamide adenine dinucleotide phosphate) oxidase, i ⁇ OS, or some peroxidases. .
- ⁇ ADPH reduced, form of nicotinamide adenine dinucleotide phosphate
- i ⁇ OS oxidase
- peroxidases oxidase
- These enzyme produce high concentration of diverse free radicals including nitric oxide, superoxide anion, hydrogen peroxide, which are able to react with each other to generate more and more reactive oxygen and nitrogen species.
- Lactoferrin or related metal-binding proteins or their peptides can be used for their antiviral, antifungal or antimicrobial activities, for their antioxidant properties, for their effects on immuno-stimulation, for their anti-inflammatory, metal-binding or anti- aging effects.
- the composition can be used for its positive synergistic effect on the physiology of the liver, its anti-cancer properties, its effect on neurological disorders, its effect on healing stimulation or its growth factor activity.
- the botanical extract can be obtained from various types of plants such as algae, chlorella, or from cyanobacteria. Leaves, stems or stalks or other part of the botanical source can be used for the production of the extract.
- the extract used may contain at least one of the chromophore used by the plant or cyanobacteria in the photosynthetic pathway.
- the extract used in the composition has antioxidant effects. This extract is used for its synergetic effect on polymetal-binding proteins, lactoferrin or related metal- binding proteins or derivatives or fragments thereof, which can improve or complete the action of metal-binding proteins.
- Formulation of the present invention can be found in the form of or integrated to different supports.
- the nutraceutical products may be presented in various forms, i.e. pills, caplets, tablets, powders or granules within a daily dose where the component of the formulation is active on the physiological function.
- compositions can be added.
- the daily dose is calculated to provide the required activity for the ingredients in the final formula.
- ingredients of the composition in a formulation for topical application, such as creams, pomades or ointments. Also in that case, concentrations of the ingredients are chosen to obtain the desired effect on the physiological targets.
- Caco-2 cells are widely used to simulate intestinal cells in model culture. These cells spontaneously differentiate after confluence. This model can be also used as a good model for studying inflammation. In this specific test, inflammation is induced by addition of inflammatory compounds, such as H 2 O 2 or some proinflammatory cytokines. Examination of the inflammation can be carried out by evaluation of the synthesis of some inflammatory markers by the Caco-2 cells. One of this marker is iNOS (inducible Nitric Oxide Synthase), which can be followed by the Western-blot test, with detection by specific antibodies. Different inflammatory agents were tested on Caco-2 cells in order to determine the best one to use in further experiments. Fig.
- iNOS inducible Nitric Oxide Synthase
- CMl Cytomix 1 (IFN- ⁇ , 1000 U/ml; IL-l ⁇ , 17 nanograms/ml and TNF- ⁇ , 10 ng ml)
- CM2 Cytomix 2 (IFN- ⁇ , 600 U/ml; IL-l ⁇ , 10 nanograms/ml and TNF- ⁇ , 50 ng/ml)
- CM3 Cytomix 3 (IFN- ⁇ , 200 U/ml; IL-l ⁇ , 5 nanograms/ml and TNF- ⁇ , 100 ng/ml), H 2 O 2 /CMl, CMl with H 2 0 2 /ml).
- CMl cytomix 1
- IFN-gamma 1000 U/ml
- IL-1 beta 17 nanograms/ml
- TNF-alpha 10 ng/ml
- Caco-2 cells, inflamed with CMl were treated with different concentrations of a commercial lactoferrin.
- Results of western-blot and respective density of the iNOS spots are shown in Fig. 2(Effect of different concentrations of lactoferrin on iNOS expression by Caco-2 cells inflammed with CMl. Lactoferrin concentrations are indicated in micrograms per ml). Lactoferrin decreases the synthesis of iNOS at 250, 500 and 750 micrograms per ml. A dose of 750 micrograms per ml was chosen for the other experiments.
- Caco-2 cells, inflamed with CMl were treated with a commercial algae extract (chlorella), lactoferrin, and a mixture of both at the same concentrations.
- chlorella commercial algae extract
- lactoferrin lactoferrin
- Caco-2 cells, inflamed with CMl were treated with a commercial green . tea extract at different concentrations, lactoferrin, and a mixture of both at 5 concentrations where green tea has an anti-inflammatory effect.
- Results shown in Fig. 4 (Effect of the green tea extract (TV) at different concentrations, lactoferrin at 750 micrograms per ml and mix of lactoferrin at 750 micrograms per ml and green tea extract at 100 micrograms per ml on iNOS expression by Caco-2 cells inflamed with CMl), demonstrate that the effect of green tea at 100 micrograms per ml and l o lactoferrin together decrease iNOS in a higher level than the individual compounds at the same concentrations, and that the algebrical sum of the separate effects of green tea at 100 micrograms per ml and lactoferrin is lower than the effect of the compounds together, indicating a synergistic effect between lactoferrin and green tea extract.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45693603P | 2003-03-25 | 2003-03-25 | |
US60/456,936 | 2003-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005016372A1 true WO2005016372A1 (en) | 2005-02-24 |
Family
ID=34192987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/000445 WO2005016372A1 (en) | 2003-03-25 | 2004-03-24 | Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005016372A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038291A1 (en) * | 2005-09-22 | 2007-04-05 | Mitsui Norin Co., Ltd | Black tea polyphenols and uses thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2596986A1 (en) * | 1986-04-11 | 1987-10-16 | Sederma Sa | Use of lactoferrin in cosmetic preparations acting against free radicals |
FR2641696A2 (en) * | 1986-04-11 | 1990-07-20 | Sederma Sa | Use of a mixture containing lactoferrin in cosmetic anti-free-radical preparations |
JPH0859450A (en) * | 1994-08-18 | 1996-03-05 | Kose Corp | External preparation for skin |
WO2000000214A2 (en) * | 1998-06-26 | 2000-01-06 | N.V. Nutricia | Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms |
US6231877B1 (en) * | 1998-07-03 | 2001-05-15 | Lanatech Laboratoire Nature Et Technique | Cosmetic composition exploiting synergistic radical scavenging effects |
JP2001322940A (en) * | 2000-05-12 | 2001-11-20 | Kao Corp | Cathepsin d production facilitative agent |
JP2002069443A (en) * | 2000-08-30 | 2002-03-08 | Microalgae Corporation | Antioxidant and cosmetic containing the antioxidant |
US20030022818A1 (en) * | 1999-10-08 | 2003-01-30 | Guy Miller | Formulations of tocopherols and methods of making and using them |
-
2004
- 2004-03-24 WO PCT/CA2004/000445 patent/WO2005016372A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2596986A1 (en) * | 1986-04-11 | 1987-10-16 | Sederma Sa | Use of lactoferrin in cosmetic preparations acting against free radicals |
FR2641696A2 (en) * | 1986-04-11 | 1990-07-20 | Sederma Sa | Use of a mixture containing lactoferrin in cosmetic anti-free-radical preparations |
JPH0859450A (en) * | 1994-08-18 | 1996-03-05 | Kose Corp | External preparation for skin |
WO2000000214A2 (en) * | 1998-06-26 | 2000-01-06 | N.V. Nutricia | Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms |
US6231877B1 (en) * | 1998-07-03 | 2001-05-15 | Lanatech Laboratoire Nature Et Technique | Cosmetic composition exploiting synergistic radical scavenging effects |
US20030022818A1 (en) * | 1999-10-08 | 2003-01-30 | Guy Miller | Formulations of tocopherols and methods of making and using them |
JP2001322940A (en) * | 2000-05-12 | 2001-11-20 | Kao Corp | Cathepsin d production facilitative agent |
JP2002069443A (en) * | 2000-08-30 | 2002-03-08 | Microalgae Corporation | Antioxidant and cosmetic containing the antioxidant |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch Week 199619, Derwent World Patents Index; Class B04, AN 1996-184671, XP002285568 * |
DATABASE WPI Section Ch Week 200233, Derwent World Patents Index; Class B04, AN 2002-285829, XP002285567 * |
DATABASE WPI Section Ch Week 200256, Derwent World Patents Index; Class A96, AN 2002-522564, XP002285569 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038291A1 (en) * | 2005-09-22 | 2007-04-05 | Mitsui Norin Co., Ltd | Black tea polyphenols and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5269466B2 (en) | Composition for ingestion | |
US9089576B2 (en) | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin | |
He et al. | Effect of selenylation modification on antitumor activity of peptidoglycan from Lactobacillus acidophilus | |
WO2007049400A1 (en) | Composition for promoting the production of collagen and/or hyaluronic acid | |
Arcanjo et al. | Resveratrol protects Lactobacillus reuteri against H2O2-induced oxidative stress and stimulates antioxidant defenses through upregulation of the dhaT gene | |
KR102385070B1 (en) | Composition for preventing, improving, or treating inflammation comprising peptides derived From Haliotis Discus as effective component | |
JP2018523703A (en) | Anti-inflammatory peptides and uses thereof | |
Lee et al. | Medicinal effects of bromelain (Ananas comosus) targeting oral environment as an anti-oxidant and anti-inflammatory agent | |
Yang et al. | Polyphyllin I inhibits Propionibacterium acnes-induced IL-8 secretion in HaCaT cells by downregulating the CD36/NOX1/ROS/NLRP3/IL-1β pathway | |
JP2015129112A (en) | Catalase expression-inducing agents | |
Sowmya et al. | Antioxidative and anti-inflammatory potential with trans-epithelial transport of a buffalo casein-derived hexapeptide (YFYPQL) | |
JP2022079551A (en) | Composition for inhibiting myofibrosis | |
KR20180035829A (en) | Growth promoting peptides and uses thereof | |
KR20060037245A (en) | Skin collagen production promoter | |
KR20160021734A (en) | Antioxidative composition comprising extract of red tea stem | |
WO2014203883A1 (en) | Hyaluronic acid production promoter | |
WO2012043714A1 (en) | Skin collagen production-promoting agent | |
KR20130114141A (en) | Skin collagen production-promoting agent | |
EP4071241A1 (en) | Mono-hydroxy or di-hydroxy derivatives of polyunsaturated fatty acids, production method therefor, and use thereof | |
US20120231071A1 (en) | Natural product inhibitors of 3dg | |
WO2005016372A1 (en) | Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals | |
KR101753874B1 (en) | A cosmetic composition comprising a decapeptide as an active ingredient | |
Girgih et al. | Effect of peptide size on the antioxidant properties of giant African land snail (Archachatina marginata) meat protein hydrolysates. | |
JP2013166719A (en) | Ampk activator | |
KR102569055B1 (en) | Oral composition comprising beta-escine for reducing acetaldehyde toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |